Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Insulin Resistance in Obese African American Women
NCT01334554Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2011
- Primary completion
- Aug 2013
- Countries
- 1
- Sponsor
- Vanderbilt University Medical Center
- Modality
- Small Molecules
- Drugs
- sildenafil
- Conditions
- metabolic syndromeinsulin resistance (IR)
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in metabolic syndrome and insulin resistance (IR), sponsored by Vanderbilt University Medical Center. Started Apr 2011; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Obese African American women with metabolic syndrome or high fasting insulin, excluding those with diabetes or cardiovascular disease.
04
Results
Not all primary endpoints met
05
Registry description
Obesity has a greater detrimental impact on the health of African American women than on any other racial or gender group. Nearly 80% of African American women are overweight or obese in the United States. Hypertension and insulin resistance are more prevalent among African American women as compared to men and Caucasians. These conditions put them at increased risk for the development of diabetes mellitus and cardiovascular disease.
Recent studies have reported that a substance named Nitric Oxide (NO)may have some beneficial effect on how the body handles blood sugar and blood pressure. Of…
Beyond the preview
Go deeper on NCT01334554.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01334554.